drugset / Trial / NCT07700121
PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma
Phase 0
Not yet recruiting
10 enrolled
Abramson Cancer Center at Penn Medicine
Iovance Biotherapeutics, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This prospective, single-center pilot study is being performed to find out whether Zr-89 crefmirlimab berdoxam "CD8 PET/CT" scans can improve the effectiveness of the tumor-infiltrating lymphocyte (TIL) therapy called lifileucel ("Study Treatment") in treating metastatic melanoma. Participants must first provide consent to the companion protocol (UPCC 19426, PICSTAT CD8 PET) before being eligible to consent to this protocol.
Timeline
- Start
- 2026-10-01
- Primary completion
- 2028-10-01
- Completion
- 2029-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | — | — |
| Background | aldesleukin | Protein / enzyme biologic | — | Intravenous |